What is the price target for WST stock?
23 analysts have analysed WST and the average price target is 328.99 USD. This implies a price increase of 35.19% is expected in the next year compared to the current price of 243.35.
WEST PHARMACEUTICAL SERVICES (WST) Forecast, Price Target & Analyst Ratings
NYSE:WST • US9553061055
Current stock price
243.35 USD
-4.77 (-1.92%)
At close:
243.35 USD
0 (0%)
After Hours:
Analyst forecast overview
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for WEST PHARMACEUTICAL SERVICES (WST).
Forecast Snapshot
Next Earnings Forecast
Earnings Estimate- Release Date
- Apr 22, 2026
- Period
- Q1 / 2026
- EPS Estimate
- $1.69
- Revenue Estimate
- 786.62M
Price Target Details & History
Consensus Price Target and Range
Mean target
$328.99
Upside
+ 35.19%
From current price of $243.35 to mean target of $328.99, Based on 23 analyst forecasts
Low
$267.65
Median
$326.40
High
$393.75
Price Target Revisions
1 Month
-6.91%
3 Months
-5.85%
Price Target Summary
23 Wall Street analysts provided a forecast for the next 12 months for WST. The average price target is 328.99 USD. This implies a price increase of 35.19% is expected in the next year compared to the current price of 243.35.
The average price target has been revised downward by 5.85% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
80.87%
WST was analyzed by 23 analysts. The buy percentage consensus is at 81. So analysts seem to be very confident about WST.
In the previous month the buy percentage consensus was at a similar level.
WST was analyzed by 23 analysts, which should be a sufficient number of analysts to have a meaningful average consensus rating.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-02-13 | Barclays | Maintains | Equal-Weight -> Equal-Weight |
| 2026-02-03 | Evercore ISI Group | Maintains | Outperform -> Outperform |
| 2025-12-02 | Morgan Stanley | Initiate | Equal-Weight |
| 2025-10-29 | TD Cowen | Initiate | Buy |
| 2025-10-27 | Barclays | Maintains | Equal-Weight -> Equal-Weight |
| 2025-10-24 | UBS | Maintains | Buy -> Buy |
| 2025-10-24 | Keybanc | Maintains | Overweight -> Overweight |
| 2025-10-23 | Evercore ISI Group | Maintains | Outperform -> Outperform |
| 2025-10-02 | Barclays | Maintains | Equal-Weight -> Equal-Weight |
| 2025-09-15 | Rothschild & Co | Initiate | Buy |
| 2025-07-25 | UBS | Maintains | Buy -> Buy |
| 2025-07-25 | Evercore ISI Group | Maintains | Outperform -> Outperform |
| 2025-06-24 | Barclays | Initiate | Equal-Weight |
| 2025-03-18 | Evercore ISI Group | Initiate | Outperform |
| 2025-02-14 | Keybanc | Maintains | Overweight -> Overweight |
| 2025-01-08 | Citigroup | Initiate | Buy |
| 2024-12-13 | Wolfe Research | Initiate | Peer Perform |
| 2024-12-13 | B of A Securities | Maintains | Buy -> Buy |
| 2024-12-12 | UBS | Upgrade | Neutral -> Buy |
| 2024-02-16 | UBS | Maintains | Neutral -> Neutral |
| 2024-02-13 | Keybanc | Maintains | Overweight -> Overweight |
| 2024-02-07 | Jefferies | Upgrade | Hold -> Buy |
| 2023-10-27 | Stephens & Co. | Maintains | Overweight -> Overweight |
| 2023-08-30 | Keybanc | Maintains | Overweight -> Overweight |
| 2023-08-21 | Keybanc | Maintains | Overweight -> Overweight |
Next Earnings Forecast Details
Next Earnings Details
- Release Date
- Apr 22, 2026
- Period
- Q1 / 2026
- EPS Estimate
- $1.69
- Revenue Estimate
- 786.62M
- Revenue Q2Q
- 12.70%
- EPS Q2Q
- 16.89%
- Number of Analysts
- 16
Next Earnings Revisions
Revenue (1 Month)
0.01%
Revenue (3 Months)
2.72%
EPS (1 Month)
-0.14%
EPS (3 Months)
1.86%
Next Earnings Summary
WST is expected to report earnings on 4/22/2026. The consensus EPS estimate for the next earnings is 1.69 USD and the consensus revenue estimate is 786.62M USD.
The next earnings revenue estimate has been revised upward by 2.72% in the past 3 months.
Full Analyst Estimates 2026 - 2030
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | ||
|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 2.95B 2.18% | 2.893B -1.92% | 3.074B 6.25% | 3.282B 6.76% | 3.484B 6.15% | 3.731B 7.09% | 4.011B 7.50% | 4.065B 1.35% | |
| EBITDA YoY % growth | 842.4M -3.78% | 744.9M -11.57% | 802.4M 7.72% | 881.41M 9.85% | 957.97M 8.69% | 1.061B 10.76% | 1.163B 9.61% | 1.161B -0.17% | |
| EBIT YoY % growth | 705.1M -6.60% | 589.5M -16.39% | 631M 7.04% | 701.24M 11.13% | 777.01M 10.81% | 866.79M 11.55% | 937.68M 8.18% | 957.48M 2.11% | |
| Operating Margin | 23.90% | 20.38% | 20.53% | 21.37% | 22.30% | 23.23% | 23.38% | 23.55% | |
| EPS YoY % growth | 8.08 -5.72% | 6.75 -16.46% | 7.29 8.00% | 8.10 11.14% | 8.99 11.01% | 10.14 12.76% | 10.87 7.21% | 11.47 5.53% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | |
|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | 1.69 16.89% | 2.02 9.72% | 2.07 5.63% | 2.08 2.10% | 1.89 11.23% | 2.18 8.06% | 2.33 12.69% | 2.32 11.37% |
| Revenue Q2Q % growth | 786.62M 12.70% | 826.52M 7.83% | 845.12M 5.04% | 845.83M 5.07% | 826.59M 5.08% | 878.52M 6.29% | 916.6M 8.46% | 905.62M 7.07% |
| EBITDA Q2Q % growth | 190.45M 14.52% | 220.43M -7.85% | 227.05M -23.68% | 226.99M -34.24% | 208.41M 9.43% | 236.09M 7.10% | 254.98M 12.30% | 250.27M 10.26% |
| EBIT Q2Q % growth | 146.29M 15.83% | 174.31M 10.46% | 181.57M 4.89% | 182.26M 4.87% | 161.83M 10.62% | 190.45M 9.26% | 209.39M 15.32% | 204.63M 12.27% |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
11.63%
EPS Next 5 Year
9.50%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
6.43%
Revenue Next 5 Year
5.60%
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
19.91%
EBIT Next 5 Year
13.54%
WEST PHARMACEUTICAL SERVICES / WST Forecast FAQ
What is the next earnings date for WST stock?
WEST PHARMACEUTICAL SERVICES (WST) will report earnings on 2026-04-22, before the market open.
Can you provide the consensus estimates for WEST PHARMACEUTICAL SERVICES next earnings?
The consensus EPS estimate for the next earnings of WEST PHARMACEUTICAL SERVICES (WST) is 1.69 USD and the consensus revenue estimate is 786.62M USD.
How do analysts rate WEST PHARMACEUTICAL SERVICES (WST)?
The consensus rating for WEST PHARMACEUTICAL SERVICES (WST) is 80.8696 / 100 . This indicates that analysts generally have a positive outlook on the stock.